LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
NCI
Neo-Concept International Group Holdings Limited
There isn't enough reported data to score NCI yet.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
NCI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Stable | |
| Unavailable | |
| Strong |
NCI's balance sheet is currently strong, and its profitability is stable. There isn't enough data to rate its revenue and cash flow.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
NCI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.5x | $4.21 | -18% |
| Current | 7.9x | $5.12 | — |
| Fair | 13x | $8.38 | +64% |
| Expensive | 107x | $69.87 | +1265% |
Historical ranges are pointers, not guarantees.
NCI's PE is 7.8x, but its earnings don't support one, so it isn't a reliable read right now.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
NCI Forward outlook
There aren't enough analyst estimates for NCI to show an outlook.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
NCI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.65 | -96% |
| Q4 2024 | $16.71 | +64% |
| Q4 2023 | $10.19 | -64% |
| Q4 2022 | $28.08 | +128% |
NCI has the edge over LCID in the latest year-over-year earnings comparison.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
NCI has the stronger quarterly revenue trend. Revenue is up 4.1% for LCID versus up 77% for NCI.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
NCI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $17.5M | -42% |
| Q4 2024 | $30M | +35% |
| Q4 2023 | $22.2M | +125% |
| Q4 2022 | $9.9M | -7.4% |
| Q3 2022 | $9.9M | -7.4% |
| Q2 2022 | $12.2M | +164% |
| Q1 2022 | $12.2M | +164% |
NCI's revenue is growing: $17M last quarter, up 77% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 1.3% | -1.6 points |
| Q4 2024 | 4.9% | -2.5 points |
| Q4 2023 | 5.2% | -2.3 points |
| Q4 2022 | 3% | -0.4 points |
| Q3 2022 | 3% | -0.4 points |
| Q2 2022 | 7.5% | +9 points |
| Q1 2022 | 7.5% | +9 points |
| Q4 2021 | 3.3% | N/A |
NCI's operating margin was 1.3% last quarter, down 1.6 points from the same quarter a year ago.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has the stronger cash trend. Its trailing FCF is down 75% versus its history, compared with NCI at down 156%.
NCI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $2.2M | +$2.7M |
| Q4 2024 | -$473.3K | +$6M |
| Q4 2023 | -$6.4M | -$1.6M |
| Q4 2022 | -$4.8M | -883% |
| Q3 2022 | -$4.8M | -883% |
| Q2 2022 | $2.1M | +5597% |
| Q1 2022 | $2.1M | +5597% |
NCI's free cash flow was −$9M over the past year, against −$45,684 the year before.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
NCI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.7% | +2.2K shares |
| 1 year | +13% | +7.3K shares |
NCI has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NCI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 0.4x | Very low |
| Q4 2024 | 1.3x | Healthy |
| Q4 2023 | 2.7x | Moderate |
| Q4 2022 | 4.0x | Elevated |
| Q2 2022 | 1.4x | Healthy |
| Q4 2021 | 5.8x | High |
NCI's net debt is less than a year of its operating earnings (EBITDA), down from 1.4 years a year ago.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
NCI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.9 | Neutral |
| Stochastic | 1.9 | Oversold |
NCI's weekly RSI is 34 (neutral) and its Stochastic is 2 (oversold).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
NCI PE vs Consumer Cyclical Sector
| Metric | NCI | Sector median | Relative |
|---|---|---|---|
| PE | 7.9x | 18x | 56% below |
| PE % | 34 | 24 | 10 pts above |
NCI is trading at 7.8x earnings, a 56% discount to the Consumer Cyclical sector's median of 18x, though its earnings don't support one.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
NCI has stronger trend alignment. LCID is above 0 of 5 weekly averages versus NCI above 0 of 4.
NCI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.7 | 74% below |
| 20 week MA | $67.8 | 92% below |
| 50 week MA | $117.5 | 96% below |
| 100 week MA | $125.3 | 96% below |
NCI is in a downtrend: it's below all four of its weekly moving averages, and 96% below its 100-week average.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has the edge over NCI on returns for 2026, with the stronger performance.
NCI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $601.6 | $167.0 | -72% |
| 2025 | $167.0 | $78.1 | -53% |
| 2026 YTD | $78.1 | $5.12 | -93% |
NCI has finished every year since 2024 lower, and it's down 93% so far in 2026.